• Publications
  • Influence
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.
Ligation of programmed cell death-1 (PD-1) in the tumor microenvironment is known to inhibit effective adaptive antitumor immunity. Blockade of PD-1 in humans has resulted in impressive, durableExpand
  • 53
  • 5
Abstract 1464: Inhibition of p38 MAPK in dendritic cells enhances their antigen presentation and induces Th17 T cell differentiation
Dendritic cells (DCs) are the most potent antigen-presenting cells which bridges innate and adaptive immunity, but how DC-derived signals regulate and induce T cell lineage choices remains unclear.Expand
4071 Dynamic Control of Tumor Vessels Augments Antitumor Responses
OBJECTIVES/GOALS: Our overall objective is to develop a directly observable and reproducible method of enhanced blood flow through tumor vessels (i.e. dynamic control) at the time of systemicExpand
Abstract B66: Blockade of PD-1 signaling in tumor-associated dendritic cells results in compensatory IL-10 release maintaining immune suppression in ovarian cancer microenvironments.
PD-1 and PD-L1 form a major inhibitory axis that acts to suppress tumor-rejecting effector responses. In addition to its expression and inhibitory functions in T and B cells, PD-1 has also been shownExpand
Abstract 1464: Inhibition of p38 MAPK in dendritic cells enhances their antigen presentation and induces Th17 T cell differentiation
Dendritic cells (DCs) are the most potent antigen-presenting cells which bridges innate and adaptive immunity, but how DC-derived signals regulate and induce T cell lineage choices remains unclear.Expand